Plain-English translation of NCT04977375 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether —a medication that helps your immune system fight cancer—combined with focused radiation therapy can be safely used before surgery to treat glioblastoma that has returned. Glioblastoma is an aggressive brain tumor, and this study wants to see if this combination approach might help patients whose tumors have come back after their initial treatment. Researchers will monitor how well this new treatment works and how your body tolerates it.
When glioblastoma comes back after initial treatment, patients need new options. This trial exists to test whether combining the medication with radiation might help the immune system better recognize and attack cancer cells before surgery, potentially improving outcomes for patients facing recurrence.
You likely qualify if…
You likely don't qualify if…
You would receive infusions and undergo stereotactic radiation therapy—a precise, focused form of radiation directed at your tumor. These treatments would happen before you have surgery to remove the tumor. The study will track your safety, how your immune system responds, and how well the treatment works, with special attention to whether the tumor can be removed on schedule without delays.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States